Commerzbank Aktiengesellschaft FI purchased a new position in TESARO, Inc. (NASDAQ:TSRO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,200 shares of the biopharmaceutical company’s stock, valued at approximately $867,000.
Other institutional investors have also made changes to their positions in the company. Vident Investment Advisory LLC bought a new stake in shares of TESARO in the first quarter worth about $351,000. Botty Investors LLC bought a new stake in shares of TESARO in the second quarter worth about $140,000. Meeder Asset Management Inc. bought a new stake in shares of TESARO in the first quarter worth about $177,000. Oppenheimer Asset Management Inc. increased its holdings in shares of TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,430 shares in the last quarter. Finally, BB&T Securities LLC bought a new stake in shares of TESARO in the second quarter worth about $222,000.
Several equities research analysts have issued reports on TSRO shares. Cann restated a “buy” rating and issued a $199.00 price target on shares of TESARO in a report on Monday, June 5th. Citigroup Inc. reaffirmed a “buy” rating and set a $216.00 price objective on shares of TESARO in a research report on Monday, September 11th. Robert W. Baird reaffirmed a “neutral” rating and set a $140.00 price objective (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Cowen and Company reduced their price objective on TESARO from $145.00 to $124.00 and set a “market perform” rating for the company in a research report on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. TESARO currently has a consensus rating of “Buy” and a consensus price target of $171.42.
Shares of TESARO, Inc. (NASDAQ:TSRO) opened at 119.04 on Friday. The stock has a 50 day moving average price of $121.03 and a 200-day moving average price of $138.94. TESARO, Inc. has a 52-week low of $96.52 and a 52-week high of $192.94. The firm’s market capitalization is $6.45 billion.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the firm posted ($1.28) earnings per share. The business’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities analysts forecast that TESARO, Inc. will post ($8.61) EPS for the current year.
WARNING: “Commerzbank Aktiengesellschaft FI Buys New Holdings in TESARO, Inc. (NASDAQ:TSRO)” was originally reported by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/commerzbank-aktiengesellschaft-fi-acquires-shares-of-6200-tesaro-inc-tsro/1603125.html.
In other news, Director James O. Armitage sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $1,171,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Insiders sold a total of 35,100 shares of company stock worth $4,558,765 in the last 90 days. Company insiders own 40.50% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.